Globus Medical, Inc. (NYSE:GMED – Get Free Report) Director David Davidar sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Globus Medical Stock Down 1.8%
Shares of Globus Medical stock opened at $81.02 on Thursday. The company has a market cap of $11.00 billion, a PE ratio of 18.84, a P/E/G ratio of 1.70 and a beta of 0.95. The business has a 50 day moving average of $86.03 and a 200 day moving average of $88.19. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40.
Globus Medical (NYSE:GMED – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current year.
Institutional Investors Weigh In On Globus Medical
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on GMED shares. Royal Bank Of Canada increased their price objective on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Wells Fargo & Company decreased their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Truist Financial set a $115.00 price objective on Globus Medical in a report on Wednesday, February 25th. Finally, Barclays increased their price objective on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Globus Medical presently has an average rating of “Moderate Buy” and a consensus target price of $106.36.
View Our Latest Stock Report on GMED
Globus Medical Company Profile
Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.
In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.
See Also
- Five stocks we like better than Globus Medical
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
